Emerging biomarkers for immunotherapy response in biliary tract cancers: a comprehensive review of immune checkpoint inhibitor strategies

被引：0

作者：

Lou, Yidan ^{[1
,2
]}

Chen, Yijing ^{[1
,2
]}

Guo, Kaibo ^{[2
,3
]}

Li, Binbin ^{[2
,4
]}

Zheng, Song ^{[1
,2
,3
,4
]}

机构：

[1] Zhejiang Univ, Sch Med, Hangzhou 310006, Peoples R China

[2] Hangzhou First Peoples Hosp, Dept Oncol, Hangzhou 310006, Peoples R China

[3] Westlake Univ, Affiliated Hangzhou Peoples Hosp 1, Key Lab Clin Canc Pharmacol & Toxicol Res Zhejian, Hangzhou 310006, Peoples R China

[4] Zhejiang Chinese Med Univ, Sch Clin Med 4, Dept Oncol, Hangzhou 310006, Peoples R China

来源：

BIOMARKERS IN MEDICINE | 2024年 / 18卷 / 15-16期

关键词：

biliary tract cancers; biomarkers; immune checkpoint inhibitor; microbiome; PD-L1; tumor microenvironment; TUMOR MICROENVIRONMENT; PD-1; EXPRESSION; GUT MICROBIOME; CHOLANGIOCARCINOMA; CHEMOTHERAPY; BLOCKADE; CELLS;

D O I：

10.1080/17520363.2024.2385297

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Biliary tract cancers (BTCs) have rising incidence and mortality rates. Chemotherapy's limited efficacy has led to exploring new treatments like immunotherapy. which offers modest benefits. Moreover, the identification of reliable predictive biomarkers for immune checkpoint therapy in BTCs remains elusive, hindering personalized treatment strategies. This review provides an overview of the current landscape of emerging biomarkers for immunotherapy response in BTCs. We discuss the incremental benefits of combination therapy and the evolving role of immunotherapy in managing advanced BTC. Additionally, we highlight the need for robust predictive biomarkers to optimize treatment outcomes and foster a more individualized approach to patient care. We aim to identify promising research avenues and strategies to enhance therapeutic efficacy and patient survival in BTCs.

引用

页码：703 / 715

页数：13

共 115 条

[1] Ivosidenib in IDH1-mutant, chemotherapy-refractory Croatia& cholangiocarcinoma (ClarlDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study [J].

Abou-Alfa, Ghassan K. ;

Macarulla, Teresa ;

Javle, Milind M. ;

Kelley, Robin K. ;

Lubner, Sam J. ;

Adeva, Jorge ;

Cleary, James M. ;

Catenacci, Daniel V. ;

Borad, Mitesh J. ;

Bridgewater, John ;

Harris, William P. ;

Murphy, Adrian G. ;

Oh, Do-Youn ;

Whisenant, Jonathan ;

Lowery, Maeve A. ;

Goyal, Lipika ;

Shroff, Rachna T. ;

El-Khoueiry, Anthony B. ;

Fan, Bin ;

Wu, Bin ;

Chamberlain, Christina X. ;

Jiang, Liewen ;

Gliser, Camelia ;

Pandya, Shuchi S. ;

Valle, Juan W. ;

Zhu, Andrew X. .

LANCET ONCOLOGY, 2020, 21 (06) :796-807

[2]

Affo S, 2021, CANCER CELL, V39, P883, DOI 10.1016/j.ccell.2021.05.010

[3] Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial [J].

Alley, Evan W. ;

Lopez, Juanita ;

Santoro, Armando ;

Morosky, Anne ;

Saraf, Sanatan ;

Piperdi, Bilal ;

van Brummelen, Emilie .

LANCET ONCOLOGY, 2017, 18 (05) :623-630

[4] Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients [J].

Baruch, Erez N. ;

Youngster, Ilan ;

Ben-Betzalel, Guy ;

Ortenberg, Rona ;

Lahat, Adi ;

Katz, Lior ;

Adler, Katerina ;

Dick-Necula, Daniela ;

Raskin, Stephen ;

Bloch, Naamah ;

Rotin, Daniil ;

Anafi, Liat ;

Avivi, Camila ;

Melnichenko, Jenny ;

Steinberg-Silman, Yael ;

Mamtani, Ronac ;

Harati, Hagit ;

Asher, Nethanel ;

Shapira-Frommer, Ronnie ;

Brosh-Nissimov, Tal ;

Eshet, Yael ;

Ben-Simon, Shira ;

Ziv, Oren ;

Khan, Md Abdul Wadud ;

Amit, Moran ;

Ajami, Nadim J. ;

Barshack, Iris ;

Schachter, Jacob ;

Wargo, Jennifer A. ;

Koren, Omry ;

Markel, Gal ;

Boursi, Ben .

SCIENCE, 2021, 371 (6529) :602-+

[5] Biliary Tract Cancers, Version 2.2023 Featured Updates to the NCCN Guidelines [J].

Benson, Al B., III ;

D'Angelica, Michael I. ;

Abrams, Thomas ;

Abbott, Daniel E. ;

Ahmed, Aijaz ;

Anaya, Daniel A. ;

Anders, Robert ;

Are, Chandrakanth ;

Bachini, Melinda ;

Binder, David ;

Borad, Mitesh ;

Bowlus, Christopher ;

Brown, Daniel ;

Burgoyne, Adam ;

Castellanos, Jason ;

Chahal, Prabhleen ;

Cloyd, Jordan ;

Covey, Anne M. ;

Glazer, Evan S. ;

Hawkins, William G. ;

Iyer, Renuka ;

Jacob, Rojymon ;

Jennings, Lawrence ;

Kelley, R. Kate ;

Kim, Robin ;

Levine, Matthew ;

Palta, Manisha ;

Park, James O. ;

Raman, Steven ;

Reddy, Sanjay ;

Ronnekleiv-Kelly, Sean ;

Sahai, Vaibhav ;

Singh, Gagandeep ;

Stein, Stacey ;

Turk, Anita ;

Vauthey, Jean-Nicolas ;

Venook, Alan P. ;

Yopp, Adam ;

McMillian, Nicole ;

Schonfeld, Ryan ;

Hochstetler, Cindy .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 (07) :695-704

[6] Deciphering human macrophage development at single-cell resolution [J].

Bian, Zhilei ;

Gong, Yandong ;

Huang, Tao ;

Lee, Christopher Z. W. ;

Bian, Lihong ;

Bai, Zhijie ;

Shi, Hui ;

Zeng, Yang ;

Liu, Chen ;

He, Jian ;

Zhou, Jie ;

Li, Xianlong ;

Li, Zongcheng ;

Ni, Yanli ;

Ma, Chunyu ;

Cui, Lei ;

Zhang, Rui ;

Chan, Jerry K. Y. ;

Ng, Lai Guan ;

Lan, Yu ;

Ginhoux, Florent ;

Liu, Bing .

NATURE, 2020, 582 (7813) :571-+

[7] Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice [J].

Boutsikou, Efimia ;

Domvri, Kalliopi ;

Hardavella, Georgia ;

Tsiouda, Dora ;

Zarogoulidis, Konstantinos ;

Kontakiotis, Theodoros .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10

[8] Activation of Fas/FasL pathway and the role of c-FLIP in primary culture of human cholangiocarcinoma cells [J].

Carnevale, Gianluca ;

Carpino, Guido ;

Cardinale, Vincenzo ;

Pisciotta, Alessandra ;

Riccio, Massimo ;

Bertoni, Laura ;

Gibellini, Lara ;

De Biasi, Sara ;

Nevi, Lorenzo ;

Costantini, Daniele ;

Overi, Diletta ;

Cossarizza, Andrea ;

de Pol, Anto ;

Gaudio, Eugenio ;

Alvaro, Domenico .

SCIENTIFIC REPORTS, 2017, 7

[9] Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden [J].

Chalmers, Zachary R. ;

Connelly, Caitlin F. ;

Fabrizio, David ;

Gay, Laurie ;

Ali, Siraj M. ;

Ennis, Riley ;

Schrock, Alexa ;

Campbell, Brittany ;

Shlien, Adam ;

Chmielecki, Juliann ;

Huang, Franklin ;

He, Yuting ;

Sun, James ;

Tabori, Uri ;

Kennedy, Mark ;

Lieber, Daniel S. ;

Roels, Steven ;

White, Jared ;

Otto, Geoffrey A. ;

Ross, Jeffrey S. ;

Garraway, Levi ;

Miller, Vincent A. ;

Stephens, Phillip J. ;

Frampton, Garrett M. .

GENOME MEDICINE, 2017, 9

[10] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic [J].

Chan, T. A. ;

Yarchoan, M. ;

Jaffee, E. ;

Swanton, C. ;

Quezada, S. A. ;

Stenzinger, A. ;

Peters, S. .

ANNALS OF ONCOLOGY, 2019, 30 (01) :44-56

← 1 2 3 4 5 6 7 8 9 10 →